
TY  - JOUR
AU  - Toledo-Pons, Nuria
AU  - Alonso-Fernández, Alberto
AU  - de la Peña, Mónica
AU  - Pierola, Javier
AU  - Barceló, Antonia
AU  - Fernández-Capitán, Carmen
AU  - Lorenzo, Alicia
AU  - Mejía Núñez, Juan Andrés
AU  - Carrera, Miguel
AU  - Soriano, Joan B.
AU  - Calvo, Néstor
AU  - Pinilla, Inmaculada
AU  - García-Río, Francisco
C7  - e12871
TI  - Obstructive sleep apnea is associated with worse clinical-radiological risk scores of pulmonary embolism
JO  - Journal of Sleep Research
JA  - J Sleep Res
VL  - n/a
IS  - n/a
SN  - 0962-1105
UR  - https://doi.org/10.1111/jsr.12871
DO  - doi:10.1111/jsr.12871
SP  - e12871
KW  - severity scores
KW  - sleep breathing disorder
KW  - venous thromboembolic disease
AB  - Summary Obstructive sleep apnea is a risk factor for pulmonary embolism, although its association with pulmonary embolism severity is unknown. Our objective was to study if obstructive sleep apnea is associated with worse pulmonary embolism severity scores and greater extent of arterial obstruction. In consecutive pulmonary embolism patients, we performed respiratory polygraphy and recorded sleep characteristics, classical risk factors for pulmonary embolism and physical activity 6?12 months after the pulmonary embolism episode. Simplified Geneva Prognostic Score and Pulmonary Embolism Severity Index were calculated at the time of the pulmonary embolism diagnosis. The Pulmonary Artery Obstruction Index and the right ventricle to left ventricle diameter ratio were measured by computed tomography pulmonary angiography. We included 120 patients, of whom 45.8% had moderate-severe obstructive sleep apnea (apnea?hypopnea index?>?15 hr?1). There was a larger proportion of moderate-severe obstructive sleep apnea patients in the third and fourth Pulmonary Artery Obstruction Index quartiles and in the III-V Pulmonary Embolism Severity Index levels compared with apnea?hypopnea index?<?15 hr?1 group. However, no differences were found between the proportion of patients with or without moderate-severe obstructive sleep apnea in their stratification by simplified Geneva Prognostic Score. The mean adjusted values of the simplified Geneva Prognostic Score, Pulmonary Embolism Severity Index and Pulmonary Artery Obstruction Index scores were higher in the apnea?hypopnea index?>?15 hr?1 group (p?<?.05). Multiple linear regression analysis identified apnea?hypopnea index as the only independent factor related to Pulmonary Artery Obstruction Index and Pulmonary Embolism Severity Index, whereas desaturation index was associated with simplified Geneva Prognostic Score. Patients with pulmonary embolism and moderate-severe obstructive sleep apnea had greater pulmonary artery obstruction as well as more pulmonary embolism severity, assessed by both the simplified Geneva Prognostic Score and the Pulmonary Embolism Severity Index, compared with patients with apnea?hypopnea index?≤?15 hr?1. Moreover, these prognostic indices were independently related to sleep parameters.
ER  - 

TY  - JOUR
TI  - Abstract
JO  - Pharmacoepidemiology and Drug Safety
JA  - Pharmacoepidemiol Drug Saf
VL  - 27
IS  - S2
SN  - 1053-8569
UR  - https://doi.org/10.1002/pds.4629
DO  - doi:10.1002/pds.4629
SP  - 3
EP  - 521
PY  - 2018
ER  - 

TY  - JOUR
TI  - RESEARCH POSTER ABSTRACTS
JO  - Value in Health
VL  - 13
IS  - 7
SN  - 1098-3015
UR  - https://doi.org/10.1111/j.1524-4733.2010.00793_3.x
DO  - doi:10.1111/j.1524-4733.2010.00793_3.x
SP  - A510
EP  - A567
PY  - 2010
ER  - 

TY  - JOUR
TI  - AUGIS abstracts 2019
JO  - BJS (British Journal of Surgery)
JA  - Br J Surg
VL  - 106
IS  - S7
SN  - 0007-1323
UR  - https://doi.org/10.1002/bjs.11421
DO  - doi:10.1002/bjs.11421
SP  - 5
EP  - 94
PY  - 2019
ER  - 

TY  - JOUR
AU  - Duffett, Lisa
AU  - Rodger, Marc
TI  - LMWH to prevent placenta-mediated pregnancy complications: an update
JO  - British Journal of Haematology
JA  - Br J Haematol
VL  - 168
IS  - 5
SN  - 0007-1048
UR  - https://doi.org/10.1111/bjh.13209
DO  - doi:10.1111/bjh.13209
SP  - 619
EP  - 638
KW  - antithrombotic treatment
KW  - heparin
KW  - placenta complications
KW  - pregnancy
PY  - 2015
AB  - Summary Placenta-mediated pregnancy complications, including preeclampsia, placental abruption, intrauterine growth restriction/small for gestational age and recurrent or late pregnancy loss, affect over 5% of pregnancies and can result in significant maternal and perinatal morbidity and mortality. These complications have been suggested to at least partly arise from placental insufficiency, possibly as a result of inappropriate coagulation activation. This association has led to the hypothesis that anticoagulant therapy, such as low molecular weight heparin, might reduce their occurrence. The following review will attempt to summarize the extensive research that has been performed to date exploring this hypothesis and provide guidance on the current and future role of low molecular weight heparin in women at risk for placenta-mediated pregnancy complications. A case will be made to question the widely adopted practice of prescribing low molecular weight heparin to women with prior placenta-mediated pregnancy complications and suggest possible areas for future research.
ER  - 

AU  - Robson, S. Elizabeth
AU  - Iqbal, Javed
AU  - Howarth, Edmund
C7  - pp. 105-116
TI  - Musculoskeletal Disorders
SN  - 9781405151689
UR  - https://doi.org/10.1002/9781444302448.ch9
DO  - doi:10.1002/9781444302448.ch9
SP  - 105-116
KW  - back and pelvic pain
KW  - Diastasis of recti abdominis or divarication of recti abdominis
KW  - Symphysis pubis dysfunction (SPD) encompasses symphysis pubis malfunction
KW  - hypovitaminosis D
KW  - risk factors for hypovitaminosis D/osteomalacia
KW  - osteoporosis - progressive, systemic skeletal disease
KW  - Osteoporosis associated with pregnancy and vertebral collapse in pregnancy quite rare
KW  - musculoskeletal disorders
PY  - 2015
AB  - Summary This chapter contains sections titled: Back and Pelvic Pain Diastasis Recti Abdominis Symphysis Pubis Dysfunction Hypovitaminosis D and Osteomalacia Osteoporosis Patient Organisations and Essential Reading
ER  - 

TY  - JOUR
TI  - Plenary Paper
JO  - Journal of the American Geriatrics Society
JA  - J Am Geriatr Soc
VL  - 61
IS  - s1
SN  - 9781405151689
UR  - https://doi.org/10.1111/jgs.12263
DO  - doi:10.1111/jgs.12263
SP  - S1
EP  - S232
PY  - 2013
ER  - 

TY  - JOUR
AU  - Ilich, A.
AU  - Key, N. S.
TI  - Global assays of fibrinolysis
JO  - International Journal of Laboratory Hematology
JA  - Int J Lab Hem
VL  - 39
IS  - 6
SN  - 9781405151689
UR  - https://doi.org/10.1111/ijlh.12750
DO  - doi:10.1111/ijlh.12750
SP  - e142
EP  - e143
PY  - 2017
ER  - 

TY  - JOUR
TI  - Abstract of the 35th international congress of the ISBT
JO  - Vox Sanguinis
JA  - Vox Sang
VL  - 113
IS  - S1
SN  - 9781405151689
UR  - https://doi.org/10.1111/vox.12658
DO  - doi:10.1111/vox.12658
SP  - 5
EP  - 347
PY  - 2018
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - International Journal of Laboratory Hematology
JA  - Int. Jnl. Lab. Hem.
VL  - 38
IS  - S2
SN  - 9781405151689
UR  - https://doi.org/10.1111/ijlh.12567
DO  - doi:10.1111/ijlh.12567
SP  - 1
EP  - 119
PY  - 2016
ER  - 

TY  - JOUR
TI  - Abstracts
JO  - Journal of Thrombosis and Haemostasis
VL  - 3
IS  - s1
SN  - 9781405151689
UR  - https://doi.org/10.1111/j.1538-7836.2005.0300a.x
DO  - doi:10.1111/j.1538-7836.2005.0300a.x
SP  - H01
EP  - H18
PY  - 2005
ER  - 

TY  - JOUR
TI  - RESEARCH PODIUM ABSTRACTS
JO  - Value in Health
VL  - 13
IS  - 7
SN  - 9781405151689
UR  - https://doi.org/10.1111/j.1524-4733.2010.00793_2.x
DO  - doi:10.1111/j.1524-4733.2010.00793_2.x
SP  - A503
EP  - A510
PY  - 2010
ER  - 

TY  - JOUR
TI  - Cost-Effectiveness Studies
JO  - Value in Health
VL  - 13
IS  - 7
SN  - 9781405151689
UR  - https://doi.org/10.1111/j.1524-4733.2010.00793_1.x
DO  - doi:10.1111/j.1524-4733.2010.00793_1.x
SP  - A502
EP  - A502
PY  - 2010
ER  - 

TY  - JOUR
TI  - Keyword Index
JO  - Journal of the American Geriatrics Society
VL  - 58
IS  - s1
SN  - 9781405151689
UR  - https://doi.org/10.1111/j.1532-5415.2010.02852.x
DO  - doi:10.1111/j.1532-5415.2010.02852.x
SP  - 269
EP  - 279
PY  - 2010
ER  - 

TY  - JOUR
TI  - Poster Presentations: Tuesday 21–Wednesday 22 April
JO  - Journal of Paediatrics and Child Health
JA  - J Paediatr Child Health
VL  - 51
IS  - S1
SN  - 9781405151689
UR  - https://doi.org/10.1111/jpc.12884_7
DO  - doi:10.1111/jpc.12884_7
SP  - 106
EP  - 138
PY  - 2015
ER  - 

TY  - JOUR
TI  - PAPER ABSTRACTS
JO  - Journal of the American Geriatrics Society
VL  - 53
IS  - s1
SN  - 9781405151689
UR  - https://doi.org/10.1111/j.1532-5415.2005.05304003.x
DO  - doi:10.1111/j.1532-5415.2005.05304003.x
SP  - S1
EP  - S217
PY  - 2005
ER  - 

TY  - JOUR
AU  - Hans, Gregory A.
AU  - Besser, Martin W.
TI  - The place of viscoelastic testing in clinical practice
JO  - British Journal of Haematology
JA  - Br J Haematol
VL  - 173
IS  - 1
SN  - 9781405151689
UR  - https://doi.org/10.1111/bjh.13930
DO  - doi:10.1111/bjh.13930
SP  - 37
EP  - 48
KW  - coagulation
KW  - TEG®
KW  - ROTEM®
KW  - thromboelastography
KW  - thromboelastometry
PY  - 2016
AB  - Summary Hellmut Hartert was the first person to exploit the viscoelastic properties of clotting blood to measure blood coagulation in 1948. Since then, the technology has improved, allowing these analyses to be performed as point-of-care tests with immediately-available results. The addition of several activators and inhibitors to the original assay creates a panel of tests able to quantify the different aspects of blood clotting that can rival conventional laboratory assays. However, although much progress has been made, the standardization and validation of these tests still need improvement. Viscoelastic analyses of blood coagulation are mainly used to guide haemostatic therapy in bleeding patients and have proven superior to standard clotting tests in some circumstances. There is potential to extend their use to other areas, such as drug monitoring, and diagnosis and management of congenital bleeding disorders. The forthcoming cartridge-based assays are expected to improve the reliability and usability of viscoelastic assays of blood coagulation but high quality clinical trials remain urgently needed to determine their exact place, benefit and cost effectiveness.
ER  - 

TY  - JOUR
TI  - Numbered abstracts 1–283
JO  - Pharmacoepidemiology and Drug Safety
JA  - Pharmacoepidem. Drug Safe.
VL  - 8
IS  - S2
SN  - 9781405151689
UR  - https://doi.org/10.1002/(SICI)1099-1557(199908)8:2+<S79::AID-PDS429>3.0.CO;2-2
DO  - doi:10.1002/(SICI)1099-1557(199908)8:2+<S79::AID-PDS429>3.0.CO;2-2
SP  - S79
EP  - S188
PY  - 1999
ER  - 

TY  - JOUR
TI  - Oral Abstracts
JO  - International Journal of Laboratory Hematology
VL  - 30
IS  - s1
SN  - 9781405151689
UR  - https://doi.org/10.1111/j.1751-553X.2008.01061.x
DO  - doi:10.1111/j.1751-553X.2008.01061.x
SP  - 1
EP  - 57
PY  - 2008
ER  - 

TY  - JOUR
TI  - Poster Presentation Abstracts
JO  - BJU International
JA  - BJU Int
VL  - 113
IS  - S4
SN  - 9781405151689
UR  - https://doi.org/10.1111/bju.12619
DO  - doi:10.1111/bju.12619
SP  - 51
EP  - 137
PY  - 2014
ER  - 
